Displaying drugs 14326 - 14350 of 14856 in total
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
CCT-018159
Experimental
(S)-famoxadone
Experimental
SD-0006
Investigational
4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN
Experimental
Evatanepag
Evatanepag has been used in trials studying the treatment of Tibial Fractures.
Investigational
NLX-P101
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
Matched Description: … product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and …
Imiglitazar
Imiglitazar has been used in trials studying the treatment of Diabetes Mellitus.
Investigational
Displaying drugs 14326 - 14350 of 14856 in total